Vanda Pharmaceuticals (VNDA) Corporate presentation summary

Strategic overview and growth drivers

• Focus on growing and diversifying revenue with up to six approved products by end of 2026.

• Commercial portfolio includes five FDA-approved brands and a robust late-stage pipeline targeting large, unmet needs.

• Key growth drivers for 2026–2027 include Fanapt, BYSANTI, HETLIOZ, PONVORY, and NEREUS, with additional pipeline assets for 2028+.

• Emphasis on consumer engagement, access, and affordability in large markets.

Product and pipeline highlights

• Fanapt and BYSANTI approved for bipolar I disorder and schizophrenia; BYSANTI Phase III for MDD ongoing with results in Q1 2027.

• HETLIOZ approved for Non-24 and SMS; pursuing approvals for insomnia and jet lag disorder.

• PONVORY approved for relapsing MS; Phase III trials ongoing for psoriasis and ulcerative colitis.

• NEREUS approved for motion sickness; Phase III for GLP-1-induced vomiting ongoing, with results expected in 2026.

• Imsidolimab BLA for GPP accepted, with PDUFA date set for December 12, 2026.

Commercial performance and market opportunities

• Fanapt saw 32% YoY total prescription growth, 45% new prescription growth, and 76% new-to-brand prescription growth from Q1 2025 to Q1 2026.

• HETLIOZ maintains leading market share despite generic competition, with continued growth in SMS.

• PONVORY demand increased for three consecutive quarters and is now promoted nationwide.

• NEREUS targets a large motion sickness market (approx. 12 million with severe symptoms in the US) and a $50B+ GLP-1 market as an adjunct therapy.